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ABSTRACT 
RNase P is an endoribonuclease that catalyzes the removal of 5-leaders in precursor tRNAs 
(pre-tRNAs), and it functions in all three domains of life as a ribonucleoprotein (RNP). The 
holoenzymes consist of an essential, catalytic RNase P RNA subunit (RPR) and a variable 
number of RNase P protein (RPP) subunits depending on the source. Bacterial RNase P is 
comprised of one RPR and one RPP. In contrast, eukaryotic RNase P contains one RPR and 
up to 10 RPPs. Intermediate in complexity, archaeal RNase P consists of one RPR and up to 
5 RPPs. Although archaeal and eukaryal RPRs display pre-tRNA processing without RPPs, 
their activity is 10
2
 to 10
6
-fold slower than that of bacterial RPR. Despite similarities in the 
structure of all RPRs, archaeal and eukaryal RPRs are more dependent on cognate RPPs for 
biological function compared to their bacterial cousin. Recently, we have successfully 
reconstituted archaeal RNase P in vitro and begun to dissect the roles of individual subunits. 
However, the multi-subunit eukaryotic RNase P has proven refractory in this regard and 
prevented a dissection of the functional interplay between RNA and protein subunits, which 
is vital to understand protein-aided RNA catalysis in this catalytic RNP. Based on insights 
from studies on archaeal RNase P, we recently purified several human RPPs as binary 
complexes (with appropriate RPP partners) to decrease the number of possibilities in the 
order of RPP additions during human RNase P assembly in vitro. This thesis reports on 
these ongoing purifications and efforts to initiate reconstitution of the 11-subunit human 
RNase P. In parallel, we also exploited the availability of purified recombinant human RPPs 
to investigate if any of them (alone or in combinations) aid bacterial RNase P RNA 
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catalysis. Such an undertaking also gains clinical significance given the successful use of 
bacterial RNase P-based customized ribozymes for selectively cleaving oncogenic and viral 
mRNAs in human cells.  
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CHAPTER 1 
INTRODUCTION 
1.1 RNase P 
RNase P is a catalytic ribonucleoprotein (RNP) responsible for catalyzing the removal of 
the 5-leader from precursor tRNAs (pre-tRNAs) in all three domains of life (Fig. 1). It 
consists of an essential RNase P RNA subunit (RPR), and a variable number of RNase P 
protein (RPP) subunits depending on the source: 1, ≤ 5, and ≤ 10 RPPs in bacteria, 
archaea, and eukarya, respectively (1-4; Table 1). 
 
Although the RPR subunit from all 
three domains of life can
 
cleave pre-tRNA in the absence of its cognate proteins, the 
bacterial RPR is the most efficient under the in vitro conditions tested: it exhibits a kobs 
value ~ 10 min
-1
 compared to 10
-1 
and 10
-5
 min
-1
 displayed by the archaeal and eukaryal 
counterparts (5-7). There is an inverse proportionality between the RPPs and RPR-alone 
activity, with eukaryal RNase P having the highest protein: RNA mass ratio (70%), in 
comparison to 50% in archaeal and 10% in bacterial RNase P (1-4). Despite the RPRs 
from all three domains of life possessing universally conserved sequence and structural 
elements that are likely to make up the active site, the functional dependence of RPRs on 
the respective RPPs is clearly different. Given that even the single bacterial RNase P 
protein subunit assists the cognate RPR’s binding affinity for the pre-tRNA/Mg2+ and 
enhances the RPR’s cleavage rate (1, 8-11), it is of interest to determine why multiple 
RPPs are needed for the biological function of archaeal and eukaryal RNase P, and how 
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they cooperate with the single RNA moiety to create functional RNPs. Recent findings on 
archaeal RNase P are discussed below to provide a context to the specific aims on 
eukaryotic RNase P, which form the mainstay of this thesis.  
Archaeal RPRs resemble their bacterial cousin yet are associated with 5 RPPs that 
have eukaryotic homologs (POP5, RPP21, RPP29, RPP30, RPP38/L7Ae; Table 1; 4, 5, 
12). Archaeal RNase P is thus an interesting mosaic. In the Gopalan laboratory, archaeal 
RNase P from Methanococcus maripaludis (Mma), Methanothermobacter 
thermautotrophicus (Mth), Pyrococcus furiosus (Pfu), and Methanocaldococcus 
jannaschii (Mja) have been successfully reconstituted in vitro using recombinant RPR 
and RPPs (5, 13-15).
 
These biochemical studies revealed that four of the five archaeal 
RPPs function as binary complexes (RPP21•RPP29 and POP5•RPP30) and that they 
collectively increase the RPR’s kcat/Km by two to three orders of magnitude (5, 13-15). 
Also, it was observed that these RPPs cannot individually activate the archaeal RPR, 
suggesting that heterodimerization is important for function. Additionally, NMR and 
yeast two-hybrid studies provided strong evidence for heterodimerization of POP5 with 
RPP30 and RPP21 with RPP29 (16). In fact, the Gopalan laboratory has exploited these 
findings and co-overexpressed the interacting archaeal RPPs in Escherichia coli and 
purified these proteins as binary complexes under native conditions (5, 15, 16).  
Despite the recent advances in studying bacterial and archaeal RNase P, the exact 
interplay between the RNA and protein subunits in eukaryal RNase P remains elusive. So 
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far, native yeast and human RNase P have been purified to homogeneity and their subunit 
composition characterized. Human RNase P has ten RPPs associated with its RPR (H1 
RNA) (17-19). The nomenclature of the protein subunits is based largely according to the 
molecular weight of each RPP: POP1, RPP40, RPP38, RPP30, RPP29, RPP25, RPP21, 
RPP20, POP5, and RPP14 (Table 1). Yeast RNase P has one RPR and nine subunits all 
of which share homologs with the human counterpart (2, 18). Despite having in hand the 
various recombinant subunits, it has not been easy to determine why eukaryotic RNase P 
requires nine to ten RPPs for biological function. 
One approach to study the roles of human RPPs would be to biochemically 
reconstitute the human RPR (H1 RNA) with subsets of human RPPs and determine their 
effects (either alone or in combination) on RNA catalysis. In fact, such an undertaking 
revealed that human RPP21 and RPP29 facilitated H1 RNA-mediated pre-tRNA 
processing in vitro (17). The partial reconstitution of human RPR with RPP21 + RPP29 
resulted in pre-tRNA cleavage but this activity was estimated to be less than 0.01% of 
that exhibited by a purified HeLa nuclear RNase P (20). Moreover, this activity could not 
be increased further upon addition of any of the remaining eight RPPs. Thus, it is unclear 
if the RNP complex consisting of H1 RNA + RPP21 + RPP29 is a true intermediate in 
the assembly towards the complete holoenzyme. Regardless, we have decided to adopt a 
slightly different approach to this daunting problem of reconstituting a 11-member RNP 
complex. 
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Given our recent successes with binary RPP complexes, our specific goal is to co-
overexpress and purify human RPPs as binary complexes, with the expectation that such 
an approach can preserve the active conformations of human RPPs and thus facilitate 
successful in vitro reconstitution of human RNase P.  Importantly, this should simplify 
the number of assembly paths and possible intermediates. 
Having purified human RPPs as binary complexes (POP5•RPP30, RPP21•RPP29, 
RPP14•RPP30 and RPP20•RPP25) will also permit us to test them for their ability to 
heterologously reconstitute with the bacterial RPR; for these studies, we typically use M1 
RNA, the RNA subunit of E. coli RNase P. These experiments will help identify if human 
RPPs promote bacterial RPR catalysis, a research goal motivated by the use of bacterial 
RNase P-derived customized ribozymes (M1GS) for selective and targeted degradation of 
viral and oncogenic mRNAs in mammalian cells.  M1GS is a customized RNA in which the 
E. coli RPR (M1 RNA) is covalently tethered to a guide sequence (GS), which is designed 
to be complementary with the target RNA (21-23; Fig. 2).
  
The guide sequence can be 
tailored to bind to any cellular RNA (e.g., oncogenic or viral mRNAs), and M1 RNA 
facilitates cleavage of the target mRNA once it is recognized and bound to the GS (21-23; 
Fig. 2). It remains unclear which human proteins assist M1GS to accomplish its task in 
human cells. Since it is conceivable that some human RPPs might act as cofactors for 
M1GS, we are also pursuing this research direction. 
 
 13 
 
CHAPTER 2 
METHODS 
2.1 Protein overexpression 
To co-overexpress human binary RPPs in Escherichia coli BL21 (DE3) cells, we used 
two compatible plasmids each encoding for one RPP gene: pET-15b (RPP30 or RPP20 or 
RPP21) and pLANT2b (RPP25 or RPP14 or POP5) (18). Note that pET-15b and 
pLANT2b confer resistance to carbenicillin and kanamycin, respectively. While E. coli 
BL21 (DE3) cells were transformed with the appropriate combination of plasmids 
(POP5•RPP30, RPP20•RPP25, RPP14•RPP30) to co-overexpress binary RPPs, E. coli 
BL21 (Rosetta) was used as the host to express RPP21 singly. Single transformants were 
picked to inoculate 6 ml of LB media containing 35 µg/ml kanamycin and 100 µg/ml 
carbenicillin (in those instances where two RPPs were being expressed from pET-15b 
and pLANT2b).  The cultures were grown overnight and used as starter cultures to 
inoculate 500 ml of LB media supplemented with the appropriate antibiotics. The cells 
were grown at 37˚C and induced at Abs600 ~ 0.6-0.8 with isopropyl-β-D-thio-galactoside 
(IPTG). Human RPP20•RPP25 was induced with 1 mM IPTG for 3 h at 37˚C, while 
POP5•RPP30 and RPP14•RPP30 were induced with 1 mM IPTG at 25˚C for 17-19 h. 
Human RPP21 was induced with 1 mM IPTG, 100 mM ZnCl2 at 25˚C for 17.5 h. These 
conditions were empirically identified to be the most optimal. 
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2.2 Purification of human binary RPP complexes 
All purifications were performed on an AKTA Purifier FPLC system. All 
chromatographic columns were purchased from GE Healthcare. All purified RPP 
complexes were dialyzed against 25 mM Tris-HCl (pH 7.5), 400 mM ammonium acetate 
and 10 mM magnesium acetate (the RNase P assay buffer which we used), supplemented 
with 25% glycerol, and stored at -20°C until further use. 
 
2.2.1 Human RPP20•RPP25 
 The frozen cell pellets from 125 ml of overexpressed culture were thawed and re-
suspended in 25 ml of buffer S [25 mM Tris-HCl (pH 7.5), 1 M NaCl, 5 mM DTT, 0.1 
mM PMSF, 1 mM EDTA]. Subsequently, the cells were lysed by sonication [4 sonication 
cycles, 1.5 min per cycle, program: 4 s on and 5 s off, amplitude: 80% (Sonics, 
VCX130)] and centrifuged at 11,000 g for 18 min at 4 ˚C to remove insoluble material 
and cell debris. The supernatant was treated with 0.05% (v/v) of polyethylenimine (PEI) 
to precipitate the nucleic acids. The PEI-precipitated nucleic acid was pelleted by 
centrifugation at 11,000 g for 18 min at 4˚C. The resulting supernatant was precipitated 
using 40% (w/v) ammonium sulfate and centrifuged at 11,000 g for 18 min at 4˚C. The 
precipitated pellet (containing RPP20•RPP25) was re-suspended in 10 ml of buffer A [25 
mM Tris- HCl (pH 7.5), 25 mM NaCl, 5 mM DTT, 0.1 mM PMSF, 1 mM EDTA] and 
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dialyzed in buffer A for 3.5 h.  The solution was filtered through a 0.45 µm filter and 
loaded on a 1-ml HiTrap SP-Sepharose column. The bound protein proteins were eluted 
with a linear (0.025-2 M) NaCl gradient. Human RPP20•RPP25 eluted between 0.68 and 
0.74 M NaCl. Subsequently, the peak fractions (identified as such by SDS-PAGE and 
Coomassie blue staining) were pooled and supplemented with NaCl to a final 
concentration of 2 M NaCl and loaded on a 1-ml HiTrap phenyl-Sepharose column.  
Bound proteins were eluted using a reverse linear (2 -0.025 M) NaCl gradient. Human 
RPP20•RPP25 eluted at 0.08 M NaCl.  
 
2.2.2 Human RPP14•RPP30 
The frozen cell pellets from 125 ml of an overexpressed culture were thawed and re-
suspended in 25 ml of buffer S (without EDTA). Subsequently, the cells were lysed by 
sonication [four sonication cycles, 1.5 min per cycle, program: 4 s on and 5 s off, 
amplitude: 80% (Sonics, VCX130)] and centrifuged at 11,000 g for 18 min at 4˚C to 
remove insoluble material and cell debris. The supernatant was treated with 0.1% (v/v) of 
polyethylenimine (PEI) to precipitate the nucleic acids, pelleted by centrifugation for 18 
min at 4˚C.  The resulting supernatant was precipitated using 40% (w/v) ammonium 
sulfate and centrifuged at 11,000 g for 18 min at 4˚C. The precipitated pellet (containing 
RPP14•RPP30) was re-suspended in 10 ml of buffer A and dialyzed for 16 h.  The 
solution was filtered through a 0.45 µm filter and loaded on a 1-ml HiTrap SP-Sepharose 
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column. Human RPP14•RPP30 eluted between 1.6 and 1.7 M NaCl. Aliquots of eluted 
fractions were analyzed for presence of RPP14•RPP30 by SDS-PAGE followed by 
Coomassie blue staining.  
 
2.2.3 Human POP5•RPP30 
 The purification protocol for human POP5•RPP30 was the same as the one employed for 
human RPP14•RPP30 with some exceptions. The protein complex eluted between 1 and 
1.1 M NaCl after cation exchange (SP Sepharose) chromatography. The peak fractions 
were pooled and supplemented with NaCl to 2 M and loaded on a 1-ml HiTrap phenyl-
Sepharose column. Bound proteins were eluted using a reverse linear (2 -0.025 M) NaCl 
gradient, and human POP5•RPP30 eluted at 0.025 M NaCl.  
 
2.2.4 Human RPP21 
The frozen cell pellets from 125 ml of an overexpressed culture were thawed and re-
suspended in 25 ml of buffer N [25 mM Tris-HCl (pH 8), 0.5 M NaCl, 0.1 mM PMSF]. 
Subsequently, the cells were lysed by sonication [four sonication cycles, 1.5 min per 
cycle, program: 4 s on and 5 s off, amplitude: 80% (Sonics, VCX130)] and centrifuged at 
11,000 g for 18 min at 4˚C to remove insoluble material and cell debris. The supernatant 
was filtered through a 0.45 µm filter and loaded on a HisTrap HP 1-ml (Nickel-
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Sepharose) column. The bound protein was eluted using a linear (0-0.3 M) imidazole 
gradient, and human RPP21 eluted at 0.06 M imidazole. The peak fractions were pooled 
and supplemented with NaCl to 2 M and loaded on a 1-ml HiTrap phenyl-Sepharose 
column. The bound protein was eluted using a reverse linear (2 -0.025 M) NaCl gradient, 
and human RPP21 eluted at 1.9 M NaCl.  
 
2.2.5 RNase P assays 
Pre-tRNA processing assays were performed with tobacco chloroplast pre-tRNA
Gly
 as the 
substrate.  For in vitro reconstitutions, RNase P was assayed in 25 mM Tris-HCl (pH 7.5), 
400 mM ammonium acetate and 10 mM magnesium acetate, and incubated at 37°C. E. coli 
RPR (M1 RNA) was folded by incubation at 50°C for 50 min, 37°C for 10 min in water, 
and    37°C for 30 min in assay buffer. Reconstitution was initiated by incubating the folded 
E. coli RPR together with human RPPs (POP5•RPP30 or RPP14•RPP30) for 10 min at 
37°C. After the holoenzyme was reconstituted (50 nM RPR and 1 μM of the specified 
binary RPP complex), the assay was initiated by adding pre-tRNA
Gly 
(250 nM, mixed with 
a trace amount of radiolabeled substrate), and incubated for 10 min. At the end of this 
incubation, RNase P reactions were quenched with an urea-phenol dye [8 M urea, 10% 
(v/v) phenol, 5 mM EDTA, 0.05% (w/v) xylene cyanol]. Reaction products were 
separated by denaturing polyacrylamide gel electrophoresis [8% (w/v) polyacrylamide 
gel, 8 M urea]. Subsequently, the products were visualized via phosphorimaging on 
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Typhoon (GE Healthcare) and quantitated by ImageQuant (GE Healthcare) to determine 
the extent of cleavage.     
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CHAPTER 3 
RESULTS & DISCUSSION 
We investigated different approaches to purify human RNase P proteins. Our overarching 
strategy though was to exploit the information on protein-protein interactions within the 
human RNP complex. This was motivated primarily by our own work with archaeal 
RPPs where we had discovered that function was dictated by heterodimerization 
(POP5•RPP30 and RPP21•RPP29) (5, 13). Moreover, yeast two-hybrid studies of human 
RNase P revealed the presence of strong protein-protein interactions between human 
POP5 and RPP30, RPP14 and RPP30, RPP20 and RPP25, RPP21 and RPP29 (2). These 
observations collectively provided the rationale to purify four different human RPP 
binary complexes (RPP14•RPP30, POP5•RPP30, RPP21•RPP29 and RPP20•RPP25).  
 
The purification scheme of each protein complex was chosen to exploit the 
proteins’ varying biochemical properties: size, charge, solubility difference, and 
hydrophobicity. PEI treatment, ammonium sulfate precipitation, cation-exchange and 
hydrophobic exchange chromatography were used to isolate the RPP pairs to 
homogeneity (Figs. 4-10). Indeed, three of the four complexes that we had set out to 
isolate were overexpressed and purified to homogeneity. These efforts were fruitful 
largely through empirical determination of different induction regimens to obtain soluble 
protein and examination of different chromatographic matrices to exploit the specific 
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biochemical features of the RPPs. It is important to point out that while affinity 
chromatography would have simplified the task of purifying these proteins, the presence 
of affinity tags (if unremoved) would have posed hurdles during assembly of this multi-
protein RNP complex. Hence we invested significant time and effort to purify these 
binary RPPs as native complexes. 
 
Although some preliminary efforts to reconstitute human RNase P RNA (H1 
RNA) with these binary RPPs were not encouraging (Lai and Gopalan, unpublished 
results), we decided to pursue heterologous reconstitution with the bacterial RPR (M1 
RNA from E. coli). We chose assay conditions that would allow for assessment of the 
beneficial effect of human binary RPPs on M1 RNA-mediated catalysis. When M1 RNA 
was reconstituted with human POP5•RPP30 and RPP14•RPP30, the holoenzyme 
exhibited multiple turnover at 37˚C with pre-tRNAGly. Based on the initial assay results, 
there was modest activation of bacterial RPR catalysis by POP5•RPP30 (Fig. 11). 
 
While there is weak pre-tRNA processing from heterologous reconstitution, we 
will continue to optimize different conditions in order to maximize bacterial RPR 
catalysis in the presence of human RPPs. Altering divalent (Mg
2+
) and monovalent 
(NH4
+
) ions would provide an array of conditions to examine if we could realize better 
activation of M1 RNA by human RPPs. Though Mg
2+ 
is vital for M1 RNA folding and 
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catalysis, high concentrations of Mg
2+
 or NH4
+
could compromise and inhibit the 
interaction of RPPs with the M1 RNA. It is also possible that high concentrations of 
ammonium acetate might help dissociate non-specific protein-RNA interactions and 
increase the hydrophobic stacking effect of RPPs. Thus finding the optimal 
concentrations of divalent (Mg
2+
) and monovalent (NH4
+
) ions in these assays will remain 
an important future goal. 
 
The heterologous reconstitution assays with bacterial RPR shows a modest 
difference between POP5•RPP30 and RPP14•RPP30. POP5•RPP30 highly activated Eco 
RPR but RPP14•RPP30 showed minimal activation of Eco RPR. Phylogenetic analyses 
suggest human POP5 and RPP14 share evolutionary ancestry and a paralogous 
relationship (Fig. 12) (24). There was an activation difference upon reconstituting these 
related binary complexes with M1 RNA, which imply that RPP14 does not behave in an 
identical fashion as POP5; in fact, it is already established that RPP14 (unlike POP5) 
does not directly interact with H1 RNA (20).  
 
Based on our results, there is a possibility that RPP14•RPP30 and POP5•RPP30 
might not be sufficient for M1 RNA or H1 RNA activation. Although we have co-
overexpressed and purified human RPP subunits as binary complexes, we have also made 
attempts at overexpressing and purifying other human RPPs as single subunits. Human 
RPP21•RPP29 was not co-overexpressed and purified successfully, but we were able to 
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overexpress and purify human RPP21 as a single RPP (Fig. 13).  The weak 
overexpression of RPP21•RPP29 could be attributed to their codon usage being 
suboptimal in E. coli. Since there is evidence of human RPP21 weakly activating H1 
RNA (17, 20), we could use RPP21 in tandem with the other purified human RPP binary 
complexes for heterologous reconstitution.  
 
Since our long-term goal is to reconstitute the human RNase P holoenzyme in 
vitro, we would need to complete purification of the entire suite of RPPs and then test 
different combinations with H1 RNA. POP1, the largest of the RPPs (~100 kDa), might 
well prove critical in providing a scaffold for RNase P assembly. If so, we will not be 
able to move forward without purifying it. Genetic studies suggest that POP1 is an 
essential RPP subunit in yeast RNase P catalysis. Mutagenizing POP1 resulted in loss of 
assembly and in vivo function of yeast RNase P (26). Our initial attempts to purify human 
POP1 revealed that it is subject to proteolysis (unpublished observations).  
 
It is possible that not all RPPs might lend themselves to the binary RPP 
purification approach. Ultimately, the challenging goal of reconstituting human RNase P 
might depend on a combinatorial approach wherein some RPPs are isolated as binary 
complexes while others as individual proteins. This thesis provides a foundation to make 
advances in this direction. 
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Precursor tRNA Mature tRNA 
RNase P 
Mg
2+ 
5′ leader 
Figure 1. 5′-Maturation of tRNAs. 
RNase P aids in tRNA biogenesis by cleaving the 5′ leader of precursor-tRNA. It 
requires Mg
2+
 as an essential cofactor.   
 
 
 
 
 
 28 
 
 
  
 
 
Figure 2. Use of customized RNase P-based ribozymes for targeted degradation of 
cellular RNAs. 
(A) M1GS uses the guide sequence (GS) to bind to the target mRNA by 
complementary base pairing thereby enabling M1 RNA to cleave the target 
mRNA. (B) I-M1GS is catalytically inactive due to point mutations in M1 RNA, 
and as a result, there is no cleavage activity. I-M1 GS is used as a negative control 
to correct for antisense effects. This figure is modified from reference 20. 
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Figure 3. Protein-protein interactions within yeast (A) and human (B) RPPs using 
yeast two-hybrid (Y2H) genetic studies and glutathione-S-transferase (GST)-based 
pull-down experiments. This figure is reproduced from reference 2. 
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Bacteria 
(Eco) 
Archaea  
(Mma) 
Eukarya 
(Hsa)  
   
RPR RPR RPR 
1 RNA 
(377 nt)                     
1 RNA  
(250 nt) 
1 RNA 
 (339 nt) 
   
RPP RPPs RPPs 
1 RPP 4-5 RPPs  10 RPPs  
C5 (14)   POP1 (115) 
    RPP40 (40) 
  L7Ae (12) RPP38 (32) 
  RPP30 (26) RPP30 (29) 
  RPP29 (11) RPP29 (25) 
   RPP25 (21) 
  POP5 (15) POP5 (19) 
  RPP21 (13) RPP21(18) 
   RPP20(16) 
  RPP14 (14) 
 
 
 
 
 
 
 
 
 
 
RPPs highlighted in bold font indicate homologs. The length of the RPR and the 
molecular weight of each RPP are provided in parentheses.  
 
Table 1 
Composition of RNase P in the three domains of life 
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          M       UI                    I 
RPP25 
RPP20 
Figure 4. SDS-PAGE analysis to demonstrate co-overexpression of recombinant 
human RPP20•RPP25.  
UI and I indicate the crude extracts from un-induced and induced cultures of E. coli 
BL21 (DE3) cells, respectively, that co-overexpress RPP20 and RPP25 from pET-
based overexpression plasmids. M denotes a reference size marker.  
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10 
17 
26 
RPP25 
RPP20 
Figure 5. SDS- PAGE analysis to demonstrate the purification of recombinant human 
RPP20•RPP25.  
UI indicate the crude extracts from un-induced  culture in E. coli BL21 (DE3) cells. 
CEC peak fractions correspond to those obtained after cation exchange 
chromatography. M denotes a reference size marker.   
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HIC        
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RPP20 
RPP25 
26 
17 
10 
kDa 
Figure 6. SDS-PAGE analysis to demonstrate purification of recombinant human 
RPP20•RPP25.  
IP comprises of pooled fractions from cation exchange chromatography, and the HIC 
peak fraction corresponds to those obtained after hydrophobic interaction 
chromatography. M denotes a reference size marker. 
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Figure 7. SDS-PAGE analysis to demonstrate purification of recombinant human 
POP5•RPP30. 
UI and I indicate the crude extracts from un-induced and induced cultures of E. coli 
BL21 (DE3) cells, respectively, that co-overexpress POP5 and RPP30 from a pET-
based overexpression plasmid. CEC peak fractions correspond to those obtained after 
cation exchange chromatography. M denotes a reference size marker.   
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Figure 8. SDS-PAGE analysis to demonstrate purification of recombinant human 
POP5•RPP30. 
IP is the input from the combined CEC peak fractions. The HIC peak fractions 
correspond to those obtained after hydrophobic interaction chromatography. M 
denotes a reference size marker. 
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Figure 9. SDS-PAGE analysis to demonstrate purification of recombinant human 
RPP14•RPP30.  
IP is the solubilized cell pellet after ammonium sulfate precipitation. M denotes a 
reference size marker. 
 37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
17 
10 
RPP14 
RPP30 
    M                            CEC peak fractions kDa 
Figure 10. SDS-PAGE analysis to demonstrate purification of recombinant human 
RPP14•RPP30.  
CEC peak fractions correspond to those obtained after cation exchange 
chromatography. M denotes a reference size marker. 
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Eco RPR 
 (50 nM) + + + - + - - 
Eco RPP  
(1 µM) - - + - - - - 
Human 
POP5•RPP30  
(1 µM) - + - - - - + 
Human 
RPP14•RPP30  
(1 µM) - - - - + + - 
 
 
 
 
 
 
 
Figure 11. Heterologous reconstitution of human binary RPPs (POP5•RPP30 or 
RPP14•RPP30) with Eco RPR.  
Results of the heterologous reconstitution of Eco RPR (M1 RNA) and human RPPs. 
RNase P was assayed in 25 mM Tris-HCl (pH 7.5), 400 mM ammonium acetate, 10 mM 
magnesium acetate, 250  nM  pre-tRNA
Gly
, and incubated at 37°C for 10 min.  
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Figure 12. A phylogenetic tree showing RPP relationships within eukaryal POP5, 
RPP14, and POP8. 
A phylogenetic tree was constructed to show the relationship among different archaeal 
and eukaryal RNase P proteins (RPP14 and POP5).  Human RPP14 and POP5 share a 
paralogous relationship. This figure is reproduced from reference 25. 
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Figure 13. SDS-PAGE analysis to demonstrate purification of recombinant human 
RPP21. 
 HIC peak fractions correspond to those obtained after hydrophobic interaction 
chromatography. M denotes a reference size marker. 
